Literature DB >> 34773343

Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.

Mahboubeh Fereidan-Esfahani1,2, Paul A Decker3, Jeanette E Eckel Passow3, Claudia F Lucchinetti1,2, Eoin Patrick Flanagan2, William Oliver Tobin1,2.   

Abstract

BACKGROUND AND
PURPOSE: Tumefactive demyelination (TD) presents with large inflammatory lesions mimicking tumors or other space-occupying lesions. Limited epidemiological, clinical and radiological data exist for TD. We aimed to report the incidence rate, and clinical and radiological features of TD in Olmsted County, Minnesota.
METHODS: We retrospectively reviewed patients with central nervous system inflammatory demyelination-related diagnostic codes (January 1, 1998 to December 31, 2018) in the Rochester Epidemiology Project database, and adjusted incidence rates by age and sex to the 2010 US total population. We used the Expanded Disability Status Scale (EDSS) to assess outcomes (index attack and last follow-up).
RESULTS: Of 792 multiple sclerosis (MS) patients, 15 (eight males, seven females) had tumefactive MS, representing 1.9% of the MS population. The median (range) age at attack onset was 34.2 (2-61) years. Tumefactive lesion was the first clinical MS attack in 8/16 patients. Cerebrospinal fluid oligoclonal bands (OCBs) were present in 8/12 patients and 11/16 patients met the Barkhof criteria for dissemination in space. Most patients remained fully ambulatory (EDSS score ≤4 in 13/16 patients [81%]) after a median (range) follow-up duration of 10.5 (1-20.5) years. Age-adjusted annual incidence rates were 0.46/100,000 (95% confidence interval [CI] 0.12-0.81) for female patients, 0.66/100,000 (95% CI 0.23-1.02) for male patients, and 0.56/100,000 [95% CI 0.28-0.83] overall. When age- and sex-adjusted to the 2010 US total population, the overall annual incidence rate was 0.57 (95% CI 0.28-0.84). Despite aggressive clinical presentation at disease onset, most patients remained fully ambulatory (EDSS score ≤4 in 13/16 patients) with a relapsing-remitting course.
CONCLUSIONS: Although incidence is rare, TD should be suspected in patients presenting with subacutely progressive neurological deficits associated with magnetic resonance imaging findings of ring enhancement, apparent diffusion coefficient restriction, and OCB on spinal fluid analysis.
© 2021 European Academy of Neurology.

Entities:  

Keywords:  Olmsted County, MN; demyelination; incidences; multiple sclerosis; tumefactive

Mesh:

Year:  2021        PMID: 34773343      PMCID: PMC8831478          DOI: 10.1111/ene.15182

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  30 in total

1.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

2.  Is size an essential criterion to define tumefactive plaque? MR features and clinical correlation in multiple sclerosis.

Authors:  Lucia Patriarca; Silvia Torlone; Fabiana Ferrari; Caterina Di Carmine; Rocco Totaro; Ernesto di Cesare; Alessandra Splendiani
Journal:  Neuroradiol J       Date:  2016-08-16

3.  Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994.

Authors:  T S Surawicz; B J McCarthy; V Kupelian; P J Jukich; J M Bruner; F G Davis
Journal:  Neuro Oncol       Date:  1999-01       Impact factor: 12.300

4.  Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Authors:  Mirja Wallner-Blazek; Alex Rovira; Massimo Fillipp; Mara A Rocca; David H Miller; Klaus Schmierer; Jette Frederiksen; Achim Gass; Hugo Gama; Charles P Tilbery; Antonio J Rocha; José Flores; Frederik Barkhof; Alexandra Seewann; Jacqueline Palace; Tarek Yousry; Xavier Montalban; Christian Enzinger; Franz Fazekas
Journal:  J Neurol       Date:  2013-04-26       Impact factor: 4.849

5.  Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

Authors:  W T Mayr; S J Pittock; R L McClelland; N W Jorgensen; J H Noseworthy; M Rodriguez
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

Review 6.  Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.

Authors:  Pedro Sánchez; Virginia Meca-Lallana; Antonio Barbosa; Rafael Manzanares; Itziar Palmí; José Vivancos
Journal:  J Neurol Sci       Date:  2017-08-12       Impact factor: 3.181

7.  Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.

Authors:  W Oliver Tobin; Alicja Kalinowska-Lyszczarz; Stephen D Weigand; Yong Guo; Nirubol Tosakulwong; Joseph E Parisi; Imke Metz; Josa M Frischer; Hans Lassmann; Wolfgang Brück; Linda Linbo; Claudia F Lucchinetti
Journal:  Neurology       Date:  2021-09-09       Impact factor: 9.910

8.  Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis.

Authors:  Evan A Jolliffe; Yong Guo; Todd A Hardy; P Pearse Morris; Eoin P Flanagan; Claudia F Lucchinetti; W Oliver Tobin
Journal:  Neurology       Date:  2021-05-19       Impact factor: 11.800

9.  Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments.

Authors:  Staley A Brod; J William Lindsey; Flavia Nelson
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-06-18

10.  Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.

Authors:  Masoud Majed; James P Fryer; Andrew McKeon; Vanda A Lennon; Sean J Pittock
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.